WO2020034945A1 - Method for preparing cyclohexane derivative - Google Patents

Method for preparing cyclohexane derivative Download PDF

Info

Publication number
WO2020034945A1
WO2020034945A1 PCT/CN2019/100364 CN2019100364W WO2020034945A1 WO 2020034945 A1 WO2020034945 A1 WO 2020034945A1 CN 2019100364 W CN2019100364 W CN 2019100364W WO 2020034945 A1 WO2020034945 A1 WO 2020034945A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
reaction
salt
acid
nucleophilic substitution
Prior art date
Application number
PCT/CN2019/100364
Other languages
French (fr)
Chinese (zh)
Inventor
黄悦
郑飞
徐辉
Original Assignee
浙江京新药业股份有限公司
上海京新生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江京新药业股份有限公司, 上海京新生物医药有限公司 filed Critical 浙江京新药业股份有限公司
Publication of WO2020034945A1 publication Critical patent/WO2020034945A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a method for preparing a cyclohexane derivative, comprising the following steps: (1) subjecting a compound SM01 and a compound SM02 or a salt thereof to a nucleophilic substitution reaction to obtain a compound A; (2) deprotecting the compound A to obtain a compound B; and (3) subjecting the compound B and an acylation reagent to an acylation reaction to obtain a cyclohexane derivative. The method provided by the present invention has less side reactions, high product yield, and high product purity, and are suitable for industrial-scale production.

Description

一种环己烷衍生物的制备方法Preparation method of cyclohexane derivative 技术领域Technical field
本发明属于药物合成领域,具体涉及一种环己烷衍生物的制备方法。The invention belongs to the field of pharmaceutical synthesis, and particularly relates to a method for preparing a cyclohexane derivative.
背景技术Background technique
CN106518841A中公开了一类环己烷衍生物或其立体异构体或盐,这些环己烷衍生物的结构如下式IB所示:CN106518841A discloses a class of cyclohexane derivatives or stereoisomers or salts thereof. The structures of these cyclohexane derivatives are shown in the following formula IB:
Figure PCTCN2019100364-appb-000001
Figure PCTCN2019100364-appb-000001
其中X为N或C;R为:Where X is N or C; R is:
Figure PCTCN2019100364-appb-000002
Figure PCTCN2019100364-appb-000002
这些环己烷衍生物对多巴胺D 3受体、5-羟色胺具有较强亲和力,而对D 2受体亲和力较弱,表现出对D 3/D 2受体的高选择性,有较强的抗精神分裂症症状作用,并且仅有极低的毒性,安全性好,可用于制备神经精神类疾病药物。 These cyclohexane derivatives have strong affinity for dopamine D 3 receptor and serotonin, but have weak affinity for D 2 receptor, showing high selectivity for D 3 / D 2 receptor and strong It has anti-schizophrenic symptoms and has only very low toxicity and good safety.
在CN106518841A中,由哌嗪先与R-Br对接形成式IV化合物,接着与4-氨基保护的环己烷乙醛进行还原胺化反应,生成化合物V,通过进一步反应制得这些环己烷衍生物II:In CN106518841A, piperazine is first docked with R-Br to form a compound of formula IV, and then subjected to a reductive amination reaction with 4-amino-protected cyclohexaneacetaldehyde to form compound V. These cyclohexane derivatives are obtained by further reaction Property II:
Figure PCTCN2019100364-appb-000003
Figure PCTCN2019100364-appb-000003
Figure PCTCN2019100364-appb-000004
Figure PCTCN2019100364-appb-000004
反应中所用的4-氨基保护的环己烷乙醛比如是反式-2-{1-[4-(N-叔丁氧碳基)氨基]环己基}-乙醛:The 4-amino protected cyclohexaneacetaldehyde used in the reaction is, for example, trans-2- {1- [4- (N-tert-butoxycarbonyl) amino] cyclohexyl} -acetaldehyde:
Figure PCTCN2019100364-appb-000005
Figure PCTCN2019100364-appb-000005
该还原胺化路线虽然反应条件温和,操作简单,但是原料反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醛的制备,或是通过反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醇经Swern氧化制得;或是通过反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙酸乙酯经二异丁基氢化铝还原制得。Swern氧化需要在低温下操作,反应条件苛刻;二异丁基氢化铝还原,也需要低温操作,且产物需经柱层析纯化,操作复杂,不适宜放大。Although the reductive amination route has mild reaction conditions and simple operation, the raw material is trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} acetaldehyde, The formula 2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethanol is prepared by Swern oxidation; or by trans-2- {1- [4- (N-tert- Butoxycarbonyl) -amino] -cyclohexyl} ethyl acetate was prepared by reduction of diisobutylaluminum hydride. Swern oxidation requires low-temperature operation and harsh reaction conditions; the reduction of diisobutylaluminum hydride also requires low-temperature operation, and the product needs to be purified by column chromatography, which is complicated and unsuitable for scale-up.
发明内容Summary of the Invention
为了克服了现有技术制备式IB的环己烷衍生物的工艺条件苛刻、产物纯度低等的缺陷,本发明提供了一种新的制备环己烷衍生物的方法,其能够以温和的反应条件和较高的收率制得环己烷衍生物IB,并且产物中杂质含量低。具体而言,本发明采用以下技术方案。In order to overcome the disadvantages of harsh process conditions and low product purity for the preparation of cyclohexane derivatives of formula IB in the prior art, the present invention provides a new method for preparing cyclohexane derivatives, which can react mildly. Conditions and higher yields yielded cyclohexane derivative IB with low impurity content in the product. Specifically, the present invention adopts the following technical solutions.
一种制备式IB所示环己烷衍生物的方法,包括以下步骤:A method for preparing a cyclohexane derivative represented by Formula IB includes the following steps:
(1)将化合物SM01与化合物SM02或其盐进行亲核取代反应,得化合物A;(1) Compound SM01 is subjected to a nucleophilic substitution reaction with compound SM02 or a salt thereof to obtain compound A;
(2)化合物A脱保护,得到化合物B或化合物B的盐;(2) deprotection of compound A to obtain compound B or a salt of compound B;
(3)化合物B或化合物B的盐,与含有N,N-二甲氨基甲酰基的酰化试剂进行酰化反应,即得化合物IB,(3) Compound B or a salt of compound B is subjected to an acylation reaction with an acylating agent containing N, N-dimethylcarbamoyl to obtain compound IB,
合成路线为:The synthetic route is:
Figure PCTCN2019100364-appb-000006
Figure PCTCN2019100364-appb-000006
其中R为:Where R is:
Figure PCTCN2019100364-appb-000007
Figure PCTCN2019100364-appb-000007
R 2为氨基保护基;L为离去基团L’或-OH。 R 2 is an amino protecting group; L is a leaving group L 'or -OH.
优选地,上述R 2为叔丁氧羰基Boc。 Preferably, the aforementioned R 2 is tert-butoxycarbonyl Boc.
其中,所述离去基团L’可为本领域中的亲核取代反应中常规的离去基团,较佳地为-OTs、-OMs、-Br、-Cl或-I。The leaving group L 'may be a conventional leaving group in a nucleophilic substitution reaction in the art, and is preferably -OTs, -OMs, -Br, -Cl, or -I.
在一种实施方式中,上述步骤(1)中当L为L’时,所述亲核取代反应的溶剂选自乙腈、N,N-二甲基甲酰胺、丙酮、或者它们两种以上的混合物。In one embodiment, when L is L ′ in the step (1), the solvent of the nucleophilic substitution reaction is selected from acetonitrile, N, N-dimethylformamide, acetone, or two or more of them. mixture.
上述亲核取代反应在碱存在下进行,所述碱选自碳酸钾、碳酸钠、三乙胺或二异丙基乙基胺。The aforementioned nucleophilic substitution reaction is performed in the presence of a base selected from potassium carbonate, sodium carbonate, triethylamine, or diisopropylethylamine.
上述亲核取代反应的反应温度为-20~180℃,反应时间为1-48h。The reaction temperature of the nucleophilic substitution reaction is -20 to 180 ° C, and the reaction time is 1-48h.
在另一种实施方式中,上述步骤(1)中当L为-OH时,所述亲核取代反应的溶剂选自甲苯、二甲苯、或者它们的混合物。In another embodiment, when L is -OH in step (1), the solvent of the nucleophilic substitution reaction is selected from toluene, xylene, or a mixture thereof.
上述亲核取代反应是在钌催化剂例如Ru 3(CO) 12的催化下进行,膦配体选自Xantphos、Ruphos或Xphos等。 The aforementioned nucleophilic substitution reaction is performed under the catalysis of a ruthenium catalyst such as Ru 3 (CO) 12 , and the phosphine ligand is selected from Xantphos, Ruphos, Xphos, and the like.
上述亲核取代反应的反应温度为-20~180℃,反应时间为1-48h。The reaction temperature of the nucleophilic substitution reaction is -20 to 180 ° C, and the reaction time is 1-48h.
在一种实施方式中,上述步骤(1)中当L为L’时,化合物SM01市售可得,或者可按本领域常规方法制得。例如化合物SM01较佳地由下述反应制得:In one embodiment, when L is L 'in the step (1), the compound SM01 is commercially available or can be prepared according to a conventional method in the art. For example, the compound SM01 is preferably prepared by the following reaction:
Figure PCTCN2019100364-appb-000008
Figure PCTCN2019100364-appb-000008
上述反应的溶剂选自二氯甲烷、四氢呋喃、甲苯、氯仿、或者它们两种以上的混合物。The solvent for the above reaction is selected from methylene chloride, tetrahydrofuran, toluene, chloroform, or a mixture of two or more thereof.
在一种实施方式中,上述反应的试剂选自对甲苯磺酰氯、甲磺酰氯、NBS、二氯亚砜、三氯氧磷、碘或三溴化磷。In one embodiment, the reagent for the above reaction is selected from p-toluenesulfonyl chloride, methanesulfonyl chloride, NBS, dichlorosulfoxide, phosphorus oxychloride, iodine, or phosphorus tribromide.
上述反应在碱存在下进行,所述碱选自三乙胺、二异丙基乙基胺或咪唑。The above reaction is performed in the presence of a base selected from triethylamine, diisopropylethylamine or imidazole.
上述反应的反应温度为-20~180℃,反应时间为1-48h。The reaction temperature of the above reaction is -20 to 180 ° C, and the reaction time is 1-48h.
在一种实施方式中,上述步骤(1)中,除化合物SM01外,另一反应原料为化合物SM02或者化合物SM02的盐。其中化合物SM02的盐优选自盐酸盐、硫酸盐、醋酸盐、磺酸盐、甲磺酸盐或对甲苯磺酸盐。In one embodiment, in step (1) above, in addition to the compound SM01, another reaction raw material is the compound SM02 or a salt of the compound SM02. Among them, the salt of compound SM02 is preferably selected from hydrochloride, sulfate, acetate, sulfonate, mesylate or p-toluenesulfonate.
化合物SM02的盐可以由化合物SM02与酸反应制得,所述酸选自盐酸、硫酸、醋酸、磺酸、甲磺酸或对甲苯磺酸。The salt of compound SM02 can be prepared by reacting compound SM02 with an acid selected from hydrochloric acid, sulfuric acid, acetic acid, sulfonic acid, methanesulfonic acid, or p-toluenesulfonic acid.
化合物SM02或其盐可按本领域常规方法制得,例如,SM02化合物的盐可由SM02化合物与酸反应制得,或者,也可以由下式的SM02-A直接反应制得。相应地,SM02游离碱可以由SM02-A直接反应制得,或者,也可以由SM02-A的盐进一步游离制得。例如,化合物SM02较佳地通过包含下述步骤的方法制得:The compound SM02 or a salt thereof can be prepared according to a conventional method in the art. For example, the salt of the SM02 compound can be prepared by reacting the SM02 compound with an acid, or can also be prepared by directly reacting SM02-A of the following formula. Correspondingly, the SM02 free base can be prepared by directly reacting SM02-A, or it can also be prepared by further freeing the salt of SM02-A. For example, the compound SM02 is preferably prepared by a method comprising the following steps:
①R-X与R 1-哌嗪进行偶联反应,生成SM02-A; ① R-X is coupled with R 1 -piperazine to form SM02-A;
②SM02-A脱保护,得到化合物SM02或SM02的盐,②SM02-A is deprotected to obtain the compound SM02 or SM02 salt,
合成路线为:The synthetic route is:
Figure PCTCN2019100364-appb-000009
Figure PCTCN2019100364-appb-000009
其中,X为Cl、Br或I;R 1为氨基保护基。 Wherein, X is Cl, Br or I; R 1 is an amino protecting group.
R 1较佳地为Boc。 R 1 is preferably Boc.
上述步骤①中所述偶联反应是在钯催化剂催化下进行,所述钯催化剂选自 Pd 2(dba) 3、四三苯基膦钯或dppf二氯化钯,膦配体为BINAP。 The coupling reaction in the above step ① is performed under the catalysis of a palladium catalyst selected from Pd 2 (dba) 3 , tetratriphenylphosphine palladium or dppf palladium dichloride, and the phosphine ligand is BINAP.
上述步骤①中所述偶联反应在碱存在下进行,所用的碱优选自叔丁醇钾、叔丁醇钠、碳酸钾或碳酸铯。The coupling reaction in the above step ① is performed in the presence of a base. The base used is preferably potassium tert-butoxide, sodium tert-butoxide, potassium carbonate or cesium carbonate.
上述步骤①中所述偶联反应的溶剂选自甲苯、二甲苯或者它们的混合物。The solvent of the coupling reaction in step ① is selected from toluene, xylene or a mixture thereof.
在一种实施方式中,步骤(2)中所述脱保护反应的所述脱保护的方法和条件可为本领域此类反应的常规方法和条件。溶剂选自二氯甲烷、四氢呋喃、甲基四氢呋喃、甲醇、乙醇、乙酸乙酯、或者它们两种以上的混合物。In one embodiment, the methods and conditions for the deprotection of the deprotection reaction in step (2) may be the conventional methods and conditions for such reactions in the art. The solvent is selected from methylene chloride, tetrahydrofuran, methyltetrahydrofuran, methanol, ethanol, ethyl acetate, or a mixture of two or more thereof.
上述步骤(2)所述脱保护反应可以在酸存在下进行,所用的酸选自氯化氢(比如氯化氢乙醇溶液)、盐酸、硫酸或对甲苯磺酸。The deprotection reaction in step (2) can be performed in the presence of an acid, and the acid used is selected from hydrogen chloride (such as a hydrogen chloride ethanol solution), hydrochloric acid, sulfuric acid, or p-toluenesulfonic acid.
所述化合物B的盐可为本领域常规的盐,例如盐酸盐、硫酸盐或对甲苯磺酸盐。The salt of the compound B may be a salt conventional in the art, such as a hydrochloride, a sulfate, or a p-toluenesulfonate.
上述步骤(2)所述脱保护反应的反应温度为-80~100℃,反应时间为1-48h。The reaction temperature of the deprotection reaction in the above step (2) is -80 to 100 ° C, and the reaction time is 1-48h.
在一种实施方式中,上述步骤(3)所述酰化反应的方法和条件可为本领域此类反应的常规方法和条件。所述酰化反应的溶剂优选自二氯甲烷,四氢呋喃,甲基四氢呋喃,DMF,乙腈,甲苯,或者它们两种以上的混合物。In one embodiment, the methods and conditions of the acylation reaction described in step (3) above may be conventional methods and conditions of such reactions in the art. The solvent for the acylation reaction is preferably from dichloromethane, tetrahydrofuran, methyltetrahydrofuran, DMF, acetonitrile, toluene, or a mixture of two or more thereof.
上述步骤(3)所述酰化反应的酰化试剂选自N,N-二甲氨基甲酰氯、CDI(N,N'-羰基二咪唑)和二甲胺、三光气和二甲胺。The acylating reagent in the acylation reaction in step (3) is selected from the group consisting of N, N-dimethylcarbamoyl chloride, CDI (N, N'-carbonyldiimidazole), and dimethylamine, triphosgene, and dimethylamine.
上述步骤(3)所述酰化反应在碱存在下进行,所用的碱选自:有机碱如三乙胺、DIPEA(N,N-二异丙基乙胺)或DBU(二氮杂二环)等,无机碱如氢氧化钠、氢氧化钾、碳酸钠、碳酸钾或碳酸氢钠,碱的当量为1~10eq。The acylation reaction in the above step (3) is performed in the presence of a base. The base used is selected from the group consisting of an organic base such as triethylamine, DIPEA (N, N-diisopropylethylamine), or DBU (diazabicyclo). ), Etc., for inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate or sodium bicarbonate, the equivalent of the base is 1 to 10 eq.
上述步骤(3)所述酰化反应的反应温度优选为-20~100℃,反应时间优选为1-48h。The reaction temperature of the acylation reaction in the step (3) is preferably -20 to 100 ° C, and the reaction time is preferably 1-48 h.
本发明的制备方法能够以温和的反应条件和较高的收率制备得到式IB的环己烷衍生物,并且产物中杂质如二聚体杂质(或称双取代杂质)imp6和imp8、以及单甲基杂质imp1含量低,比如imp1含量低于0.1%,imp6含量低于0.3%,imp8几乎检测不出,因而产品纯度高,容易达到药物质量标准,更适合工业化大规模生产含量低。The preparation method of the present invention can prepare a cyclohexane derivative of Formula IB under mild reaction conditions and high yields, and impurities in the product such as dimer impurities (also known as disubstituted impurities) imp6 and imp8, and mono The content of methyl impurity imp1 is low, for example, the content of imp1 is less than 0.1%, the content of imp6 is less than 0.3%, and imp8 is almost undetectable. Therefore, the product has high purity, easily meets drug quality standards, and is more suitable for industrial large-scale production with low content.
具体实施方式detailed description
本文中,有时将术语“式X所示化合物”表述为“化合物X”,这是本领域技术人员能够理解的。比如式A所示化合物和化合物A都是指代相同的化合物。类似地,式IB所示化合物和化合物IB都是指代相同的化合物。Herein, the term "compound X" is sometimes expressed as "compound X", which can be understood by those skilled in the art. For example, the compound represented by formula A and compound A both refer to the same compound. Similarly, both the compound represented by Formula IB and Compound IB refer to the same compound.
本文中,化合物imp6和imp8属于二聚体杂质,化合物imp1属于单甲基杂质(或称掉甲基杂质、去甲基杂质、单杂)。In this paper, the compounds imp6 and imp8 belong to the dimer impurity, and the compound imp1 belongs to the monomethyl impurity (also called methyl impurity, demethyl impurity, mono impurity).
Figure PCTCN2019100364-appb-000010
Figure PCTCN2019100364-appb-000010
在优选的实施方式中,在上述各步骤反应完成后,可按本领域常识进行过滤、洗涤、干燥等纯化操作。In a preferred embodiment, after the reaction of the above steps is completed, purification operations such as filtration, washing, and drying may be performed according to common knowledge in the art.
应理解,当式IB的环己烷衍生物具有特定的立体构型,则按照本领域常识,化合物SM01以及其相应的反应原料都具有相对应的立体构型。例如,在一具体实施方式中,式IB化合物为N’-[反式-4-[2-[7-(苯并[b]噻吩)-7-哌嗪基]乙基]环己基]-N,N-二甲基脲(下式IB-1)时,则SM01为1,1-二甲基-3-(反式-4-(2-氧代乙基)环己基)脲,可采用反式-2-(4-氨基环己基)乙酸乙酯制备该SM01。It should be understood that when the cyclohexane derivative of Formula IB has a specific stereo configuration, according to common knowledge in the art, the compound SM01 and its corresponding reaction raw material have corresponding stereo configurations. For example, in a specific embodiment, the compound of Formula IB is N '-[trans-4- [2- [7- (benzo [b] thiophene) -7-piperazinyl] ethyl] cyclohexyl]- In the case of N, N-dimethylurea (the following formula IB-1), SM01 is 1,1-dimethyl-3- (trans-4- (2-oxoethyl) cyclohexyl) urea, but The SM01 was prepared using trans-2- (4-aminocyclohexyl) ethyl acetate.
Figure PCTCN2019100364-appb-000011
Figure PCTCN2019100364-appb-000011
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。On the basis of conforming to common knowledge in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain each preferred embodiment of the present invention.
以下通过实施例进一步阐述本发明。应理解,这些实施例仅用于举例说明目的,而不是对本发明的限制。本领域技术人员根据本发明构思对其作出的各种改变或调整,均应落入本发明的保护范围内。The invention is further illustrated by the following examples. It should be understood that these examples are for illustrative purposes only and are not a limitation on the present invention. Various changes or adjustments made by those skilled in the art according to the concept of the present invention shall fall within the protection scope of the present invention.
本文中涉及到多种物质的添加量、含量及浓度,其中所述的百分含量,除特别说明外,皆指质量百分含量。This article refers to the added amount, content and concentration of various substances, where the percentage content, unless otherwise specified, refers to the mass percentage content.
本文的实施例中,如果对于反应温度或操作温度没有做出具体说明,则该温度通常指室温(15-30℃)。In the examples herein, if no specific description is made as to the reaction temperature or the operating temperature, the temperature generally refers to room temperature (15-30 ° C).
实施例Examples
试剂:本发明实施例中使用的反应物和催化剂均为化学纯,可直接使用或根据需要经过简单纯化;有机溶剂等均为分析纯,直接使用。试剂均购自中国医药(集团)上海化学试剂公司。Reagents: The reactants and catalysts used in the examples of the present invention are chemically pure and can be used directly or simply purified as required; organic solvents and the like are all analytically pure and used directly. Reagents were purchased from China Pharmaceutical (Group) Shanghai Chemical Reagent Company.
检测仪器:Testing equipment:
核磁共振仪型号:Bruker avance HD 600MHz,Bruker avance III 400MHz;Model of nuclear magnetic resonance instrument: Bruker AV HD 600MHz, Bruker AV III III 400MHz;
质谱仪(液质联用(LCMS)),型号:Agilent 6120 B,检测器为DAD。Mass spectrometer (liquid mass spectrometry (LCMS)), model: Agilent 6120, B, and detector is DAD.
实施例1 化合物SM02的制备Example 1 Preparation of Compound SM02
Figure PCTCN2019100364-appb-000012
Figure PCTCN2019100364-appb-000012
于500ml单口烧瓶中,加入7-溴苯并噻吩(21.2g,0.1mol),Boc哌嗪(20.5g,0.11mol,1.1eq),叔丁醇钾(16.8g,0.15mol,1.5eq),甲苯(300ml)混合搅拌,氮气置换3次。加入BINAP(3.74g),Pd 2(dba) 3(2g)后,氮气置换3次。放入油浴中升温至100℃,搅拌反应过夜(8h)。取样点板(展开剂:石油醚:乙酸乙酯=10:1),原料基本反应完全。停止加热,待反应液冷却至室温后,硅藻土抽滤,滤饼用甲苯(300ml)淋洗,合并滤液,饱和食盐水洗涤,旋干(水浴45℃~60℃),得到棕红色油状物38g。经柱层析纯化,洗脱剂:石油醚:乙酸乙酯=50:1~30:1,得到淡黄色油状物21.2g,即为中间体SM02-A。 In a 500ml single-necked flask, add 7-bromobenzothiophene (21.2g, 0.1mol), Boc piperazine (20.5g, 0.11mol, 1.1eq), potassium tert-butoxide (16.8g, 0.15mol, 1.5eq) Toluene (300 ml) was mixed and stirred, and replaced with nitrogen three times. After adding BINAP (3.74 g) and Pd 2 (dba) 3 (2 g), nitrogen was substituted 3 times. The temperature was raised to 100 ° C in an oil bath, and the reaction was stirred overnight (8h). Sampling point plate (developing solvent: petroleum ether: ethyl acetate = 10: 1), the raw material reaction was basically complete. Stop heating, and after the reaction solution was cooled to room temperature, filter through diatomaceous earth, rinse the filter cake with toluene (300ml), combine the filtrate, wash with saturated brine, and spin dry (water bath 45 ℃ ~ 60 ℃) to obtain a brown-red oil.物 38g. Purified by column chromatography, eluent: petroleum ether: ethyl acetate = 50: 1 to 30: 1, to obtain 21.2 g of a pale yellow oil, which is the intermediate SM02-A.
于500L单口烧瓶中,加入中间体SM02-A(21.2g),氯化氢乙醇溶液(20ml),无水乙醇(150ml)混合,油浴55℃加热反应2h,反应过程中有白色固体析出。取样点板(展开剂:石油醚:乙酸乙酯=10:1),原料基本反应完全。停止加热,待反应液冷却至室温后,抽滤,滤饼用乙醇淋洗,烘干后得到类白色固体15g,为SM02盐酸盐。In a 500L single-necked flask, the intermediate SM02-A (21.2 g), a hydrogen chloride ethanol solution (20 ml), and anhydrous ethanol (150 ml) were added and mixed. The oil bath was heated at 55 ° C for 2 hours to react, and a white solid precipitated during the reaction. Sampling point plate (developing solvent: petroleum ether: ethyl acetate = 10: 1), the raw material reaction was basically complete. Stop heating. After the reaction solution was cooled to room temperature, suction filtration was performed. The filter cake was rinsed with ethanol. After drying, 15 g of off-white solid was obtained as SM02 hydrochloride.
上述15g盐酸盐经氢氧化钠溶液游离后,DCM萃取,饱和食盐水洗涤,无水硫酸钠干燥,抽滤旋干后,得到黄色油状物12g,为化合物SM02。After 15 g of the above-mentioned hydrochloride was freed with sodium hydroxide solution, it was extracted with DCM, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered and spin-dried to obtain 12 g of a yellow oily compound SM02.
实施例2 反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙基-4-甲基苯磺酸酯(化合物SM01)的制备Example 2 Preparation of trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethyl-4-methylbenzenesulfonate (compound SM01)
Figure PCTCN2019100364-appb-000013
Figure PCTCN2019100364-appb-000013
于100ml单口烧瓶中,加入反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醇(3.74g,0.0154mol),三乙胺(4.7g,0.0463mol,3eq),二氯甲烷(40ml)混合搅拌,分批加入对甲苯磺酰氯(3.5g,0.0185mol,1.2eq)。加毕,搅拌反应过夜。取样检测原料反应完全后,将反应液倒入冰的1N稀盐酸(50ml)中,搅拌15min,分液,水相用二氯甲烷(40ml*2)萃取,合并有机相,用饱和碳酸氢钠水溶液洗涤一次,再用饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干,得粗品,经石油醚打浆,过滤得到白色固体3.8g,即为反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙基-4-甲基苯磺酸酯SM01。In a 100 ml single-necked flask, add trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethanol (3.74 g, 0.0154 mol), and triethylamine (4.7 g, 0.0463). mol, 3 eq), dichloromethane (40 ml) and stirred, and p-toluenesulfonyl chloride (3.5 g, 0.0185 mol, 1.2 eq) was added in portions. After the addition, the reaction was stirred overnight. Sampling to check the reaction of the raw materials, the reaction solution was poured into iced 1N dilute hydrochloric acid (50ml), stirred for 15min, the liquid phase was separated, the aqueous phase was extracted with dichloromethane (40ml * 2), the organic phases were combined, and saturated sodium bicarbonate was used The aqueous solution was washed once, and then washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain a crude product. After beating with petroleum ether, it was filtered to obtain 3.8 g of a white solid, which was trans-2- {1- [4 -(N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethyl-4-methylbenzenesulfonate SM01.
实施例3 化合物A的制备Example 3 Preparation of Compound A
Figure PCTCN2019100364-appb-000014
Figure PCTCN2019100364-appb-000014
于500ml单口烧瓶中,加入SM02(12g,0.055mol,1eq),碳酸钾(15.2g,0.11mol,2eq),乙腈(300ml)混合搅拌;加入SM01(24.0g,0.0605mol,1.1eq)加毕,油浴升温至75℃,搅拌反应过夜(8h)。取样点板(展开剂:二氯甲烷:甲醇=10:1),SM02基本反应完全,停止加热,待反应液冷却至室温后,旋干溶剂,残留物加水和乙酸乙酯溶解,搅拌溶清后,分液,水相用乙酸乙酯萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干,得到淡黄色固体28g,即为化合物A粗品。In a 500ml single-necked flask, add SM02 (12g, 0.055mol, 1eq), potassium carbonate (15.2g, 0.11mol, 2eq), and acetonitrile (300ml) and stir; add SM01 (24.0g, 0.0605mol, 1.1eq) and add. The oil bath was warmed to 75 ° C and the reaction was stirred overnight (8h). Sampling point plate (developing solvent: dichloromethane: methanol = 10: 1), SM02 basically completed the reaction, stop heating, after the reaction solution was cooled to room temperature, the solvent was spin-dried, the residue was dissolved by adding water and ethyl acetate, and stirred to dissolve. Then, the layers were separated, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered with suction, and dried to obtain 28 g of a pale yellow solid, which was the crude compound A.
经柱层析纯化,洗脱剂:石油醚:乙酸乙酯=5:1~2:1~0:1,得到淡黄色固体23.3g。Purified by column chromatography, eluent: petroleum ether: ethyl acetate = 5: 1 to 2: 1 to 0: 1, to obtain 23.3 g of a pale yellow solid.
实施例4 化合物B的制备Example 4 Preparation of Compound B
Figure PCTCN2019100364-appb-000015
Figure PCTCN2019100364-appb-000015
于2L单口烧瓶中,加入化合物A(100g),无水乙醇700ml,混合搅拌,加入氯化氢乙醇溶液(100ml)后,油浴升温55℃搅拌反应,随着反应有白色固体析出,反应2h后,取样检测中间体A反应完全,停止加热,待反应液冷却至室温后,抽滤,滤饼用乙醇淋洗,烘干后得到类白色固体85g,即为化合物B的二盐酸盐。In a 2L single-necked flask, add compound A (100g), 700ml of absolute ethanol, mix and stir, add hydrogen chloride ethanol solution (100ml), and stir the reaction at 55 ° C in an oil bath. A white solid precipitates with the reaction. Samples were taken to test that the reaction of intermediate A was complete. The heating was stopped. After the reaction solution was cooled to room temperature, suction filtration was performed. The filter cake was rinsed with ethanol.
实施例5 化合物IB的制备Example 5 Preparation of Compound IB
N,N-二甲氨基甲酰氯法:N, N-dimethylcarbamoyl chloride method:
Figure PCTCN2019100364-appb-000016
Figure PCTCN2019100364-appb-000016
于2L单口烧瓶中,加入化合物B的二盐酸盐(62.28g,0.15mol),氢氧化钠水溶液(氢氧化钠60g,1.5mol,10eq,溶于375ml水中),二氯甲烷(375ml)混合,加入四丁基溴化磷(6g),搅拌溶清。冰浴冷却至5℃,滴加N,N-二甲氨基甲酰氯(64.2g,0.6mol,4eq),约45min滴完。滴毕,于25℃油浴升温搅拌反应过夜(8h)。取样检测,原料基本反应完全,反应液分液,水相二氯甲烷(200ml*2)萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干得到100g淡黄色粘稠固体,即为化合物IB粗品。In a 2L single-necked flask, add the dihydrochloride (62.28 g, 0.15 mol) of compound B, an aqueous sodium hydroxide solution (sodium hydroxide 60 g, 1.5 mol, 10 eq, dissolved in 375 ml of water), and dichloromethane (375 ml) and mixed Add tetrabutylphosphonium bromide (6g) and stir to dissolve. It was cooled to 5 ° C in an ice bath, and N, N-dimethylcarbamoyl chloride (64.2 g, 0.6 mol, 4 eq) was added dropwise, and the drop was completed in about 45 minutes. After the dropwise addition was completed, the reaction was stirred overnight (8 h) in an oil bath at 25 ° C. Sampling and detection, the basic reaction of the raw materials is complete, the reaction liquid is separated, the aqueous phase is extracted with dichloromethane (200ml * 2), the organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered with suction, and spin-dried to obtain 100 g of pale yellow viscous Thick solid, crude compound IB.
粗品经柱层析纯化,洗脱剂:二氯甲烷:甲醇=50:1~30:1,得到淡黄色固体80g,上述固体用800ml乙酸乙酯重结晶,得到化合物IB白色固体35g。The crude product was purified by column chromatography, eluent: dichloromethane: methanol = 50: 1 to 30: 1, to obtain 80 g of a pale yellow solid, and the solid was recrystallized from 800 ml of ethyl acetate to obtain 35 g of compound IB as a white solid.
1H NMR(400MHz,CDCl 3)δ:7.52 1H d,7.41 1H d,7.32 2H m,6.94 1H d,4.12 1H d,3.59 1H m,3.29 4H s,2.88 6H s,2.72 4H m,2.50 2H m,2.03 2H m,1.79 2H m,1.50 2H m,1.26 1H m,1.11 4H m; 1 H NMR (400MHz, CDCl 3 ) δ: 7.52 1H d, 7.41 1H d, 7.32 2H m, 6.94 1H d, 4.12 1H d, 3.59 1H m, 3.29 4H s, 2.88 6H s, 2.72 4H m, 2.50 2H m , 2.03 2H m, 1.79 2H m, 1.50 2H m, 1.26 1H m, 1.11 4H m;
MS(EI)m/z:M+1=415MS (EI) m / z: M + 1 = 415
经HPLC检测,HPLC纯度:imp1 0.06%;IB 99.64%;imp6 0.28%。By HPLC detection, HPLC purity: imp1 0.06%; IB 99.64%; imp6 0.28%.
杂质包含Contains impurities
Figure PCTCN2019100364-appb-000017
Figure PCTCN2019100364-appb-000017
CDI法:CDI law:
Figure PCTCN2019100364-appb-000018
Figure PCTCN2019100364-appb-000018
于100ml单口烧瓶中,加入化合物B游离碱(3.43g,0.01mol),CDI(1.78g,0.011mol,1.1eq)溶于N,N-二甲基甲酰胺(30ml)中,室温搅拌反应2h。旋干溶剂,柱层析纯化,洗脱剂:二氯甲烷:甲醇=50:1~30:1,得到白色固体3.3g(中间体)。In a 100 ml single-necked flask, add Compound B free base (3.43 g, 0.01 mol), CDI (1.78 g, 0.011 mol, 1.1 eq) and dissolve in N, N-dimethylformamide (30 ml). Stir the reaction at room temperature for 2 h. . The solvent was spin-dried and purified by column chromatography. The eluent: dichloromethane: methanol = 50: 1 to 30: 1, 3.3 g (intermediate) was obtained as a white solid.
于100ml单口烧瓶中,加入上述中间体(3.3g,0.0076mol),溶于二氯甲烷(50ml)中,加入二甲胺盐酸盐(0.92g,0.0113mol,1.5eq),三乙胺(2.1ml,0.0152mol,2eq)加毕,搅拌反应过夜。旋干反应液,柱层析纯化,洗脱剂:二氯甲烷:甲醇=50:1~30:1,得到淡黄色固体2.8g,上述固体用乙酸乙酯重结晶,得到白色固体1.2g,即为化合物IB。In a 100 ml single-necked flask, the above intermediate (3.3 g, 0.0076 mol) was added, dissolved in dichloromethane (50 ml), and dimethylamine hydrochloride (0.92 g, 0.0113 mol, 1.5 eq) and triethylamine ( 2.1 ml, 0.0152 mol, 2 eq) were added and the reaction was stirred overnight. The reaction solution was spin-dried and purified by column chromatography. The eluent: dichloromethane: methanol = 50: 1 to 30: 1, 2.8 g of a pale yellow solid was obtained. The solid was recrystallized from ethyl acetate to obtain 1.2 g of a white solid. This is compound IB.
实施例6 化合物IB的另一种制备方法Example 6 Another Preparation Method of Compound IB
Figure PCTCN2019100364-appb-000019
Figure PCTCN2019100364-appb-000019
于100ml单口烧瓶中,加入反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醇(化合物SM01C)(2.43g,0.01mol),化合物SM02游离碱(2.4g,0.011mol,1.1eq),Ru 3(CO) 12(0.25g,0.0004mol,0.04eq),Xantphos(0.35g,0.0006mol,0.06eq),甲苯(20ml)混合搅拌。氮气置换后,加热回流反应过夜。旋干溶剂,柱层析纯化,经柱层析纯化,洗脱剂:石油醚:乙酸乙酯=1:1~0:1,得到白色固体2.6g,即为化合物A。 In a 100 ml single-necked flask, add trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethanol (compound SM01C) (2.43 g, 0.01 mol), and compound SM02 free base (2.4 g, 0.011 mol, 1.1 eq), Ru 3 (CO) 12 (0.25 g, 0.0004 mol, 0.04 eq), Xantphos (0.35 g, 0.0006 mol, 0.06 eq), toluene (20 ml) and mixed with stirring. After replacing with nitrogen, the reaction was heated at reflux overnight. The solvent was spin-dried, purified by column chromatography, and purified by column chromatography. The eluent: petroleum ether: ethyl acetate = 1: 1 to 0: 1. 2.6 g of a white solid was obtained, which is compound A.
后续操作按照实施例4和5的方法制备化合物B的二盐酸盐和化合物IB。Subsequent operations The dihydrochloride of compound B and compound IB were prepared according to the methods of Examples 4 and 5.
实施例7-11 合成不同R取代基的IB化合物Examples 7-11 Synthesis of IB Compounds with Different R Substituents
参照实施例1-6中的合成方法,按下述合成路线合成不同R取代基的IB化合物。相应的结构和收率见下表1。Referring to the synthesis methods in Examples 1-6, IB compounds having different R substituents were synthesized according to the following synthetic routes. The corresponding structure and yield are shown in Table 1 below.
Figure PCTCN2019100364-appb-000020
Figure PCTCN2019100364-appb-000020
Figure PCTCN2019100364-appb-000021
Figure PCTCN2019100364-appb-000021
其中X为Br,R 1和R 2均为-Boc,L为-OTs。 Where X is Br, R 1 and R 2 are both -Boc, and L is -OTs.
表1、多种IB化合物的收率Table 1. Yields of various IB compounds
Figure PCTCN2019100364-appb-000022
Figure PCTCN2019100364-appb-000022
Figure PCTCN2019100364-appb-000023
Figure PCTCN2019100364-appb-000023
经HPLC检测,最终产物中无大于0.1%的imp1,IB化合物占99.5%以上。By HPLC detection, there was no imp1 greater than 0.1% in the final product, and the IB compound accounted for more than 99.5%.
对比例1Comparative Example 1
Figure PCTCN2019100364-appb-000024
Figure PCTCN2019100364-appb-000024
于100ml单口烧瓶中,加入化合物SM01A(1.47g,0.004mol),SM02(0.96g,0.0044mol,1.1eq),碳酸钾(1.1g,0.008mol,2eq),乙腈(40ml)混合搅匀,油浴75℃加热反应过夜。取样检测,原料反应完全后,停止加热。待反应液冷却至室温后,旋干溶剂,残留物加水(50ml)和二氯甲烷(30ml)搅拌溶清,分液。水相用二氯甲烷(50ml*2)萃取,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干,得到棕色固体2.5g。In a 100 ml single-necked flask, add the compounds SM01A (1.47 g, 0.004 mol), SM02 (0.96 g, 0.0044 mol, 1.1 eq), potassium carbonate (1.1 g, 0.008 mol, 2 eq), acetonitrile (40 ml) and mix well. Oil The reaction was heated in a bath at 75 ° C overnight. Sampling test, after the reaction of the raw materials is complete, stop heating. After the reaction solution was cooled to room temperature, the solvent was spin-dried, and the residue was stirred with water (50 ml) and dichloromethane (30 ml), and the solution was separated. The aqueous phase was extracted with dichloromethane (50 ml * 2). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered with suction, and dried to give 2.5 g of a brown solid.
经柱层析纯化,洗脱剂:二氯甲烷:甲醇=50:1~30:1,得淡黄色固体1.8g,经乙酸乙酯重结晶得到白色固体0.8g,即为化合物IB。Purified by column chromatography, eluent: dichloromethane: methanol = 50: 1 to 30: 1, 1.8 g of a pale yellow solid was obtained, and 0.8 g of a white solid was obtained by recrystallization from ethyl acetate, which is compound IB.
HPLC检测:IB 86.35%;imp8 13.22%。HPLC detection: IB 86.35%; imp8 13.22%.
含二聚物杂质imp8:Imp8 with dimer impurities:
Figure PCTCN2019100364-appb-000025
Figure PCTCN2019100364-appb-000025
对比例2Comparative Example 2
Figure PCTCN2019100364-appb-000026
Figure PCTCN2019100364-appb-000026
反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醛(化合物9-SM01)的合成:Synthesis of trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} acetaldehyde (Compound 9-SM01):
于250ml三口烧瓶中,加入DMSO(4.37g,0.056mol,3eq),溶于50ml二氯甲烷中,氮气置换,干冰浴冷却至-78℃。滴加草酰氯(4.74g,0.0373mol,2eq),控温不超过-65℃。滴毕,保温-70~-78℃反应1小时。加入反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醇的二氯甲烷溶液(反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醇,4.55g,0.0187mol溶于30ml二氯甲烷),控温不超过-65℃。滴毕,保温-70~-78℃反应1小时。加入三乙胺(26ml,0.1867mol,10eq),控温不超过-45℃。加毕,撤除干冰浴,自然升 温至-20℃,将反应液倒入冰冷的1N盐酸(100ml)中,搅拌15min。分液,水相二氯甲烷(50ml*2)萃取,合并有机相,依次用饱和碳酸氢钠水溶液、饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干得淡黄色固体5.2g。In a 250 ml three-necked flask, DMSO (4.37 g, 0.056 mol, 3 eq) was added, dissolved in 50 ml of dichloromethane, replaced with nitrogen, and cooled to -78 ° C in a dry ice bath. Oxalyl chloride (4.74 g, 0.0373 mol, 2 eq) was added dropwise, and the temperature was controlled to not exceed -65 ° C. After dripping, the reaction was held at -70 to -78 ° C for 1 hour. A solution of trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} ethanol in dichloromethane (trans-2- {1- [4- (N-tert-butyl) Oxycarbonyl) -amino] -cyclohexyl} ethanol, 4.55 g, 0.0187 mol in 30 ml of dichloromethane), and the temperature is controlled to not exceed -65 ° C. After dripping, the reaction was held at -70 to -78 ° C for 1 hour. Add triethylamine (26ml, 0.1867mol, 10eq), and control the temperature not to exceed -45 ° C. After the addition was completed, the dry ice bath was removed, and the temperature was naturally raised to -20 ° C. The reaction solution was poured into ice-cold 1N hydrochloric acid (100 ml) and stirred for 15 min. The layers were separated, and the aqueous phase was extracted with dichloromethane (50 ml * 2). The organic phases were combined, washed with saturated aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, filtered with suction, and dried to give 5.2 g of a pale yellow solid.
经柱层析纯化,洗脱剂:石油醚:乙酸乙酯=10:1~5:1,得白色固体3g,即为反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醛(化合物9-SM01)。Purified by column chromatography, eluent: petroleum ether: ethyl acetate = 10: 1 to 5: 1, 3g of white solid was obtained, which is trans-2- {1- [4- (N-tert-butoxycarbonyl) ) -Amino] -cyclohexyl} acetaldehyde (Compound 9-SM01).
化合物A的合成:Synthesis of compound A:
于100ml单口烧瓶中,加入反式-2-{1-[4-(N-叔丁氧羰基)-氨基]-环己基}乙醛(1.5g,0.00622mol),SM02游离碱(1.36g,0.00622mol,1eq),二氯甲烷(50ml)搅拌溶清。分批加入三乙酰氧基硼氢化钠(1.98g,0.00933mol,1.5eq),加毕,搅拌反应过夜。取样检测基本反应完全,反应液加入60ml饱和碳酸氢钠搅拌30min,分液,水相用二氯甲烷萃取(50ml*2),合并有机相,饱和食盐水洗涤,无水硫酸钠干燥,抽滤,旋干,柱层析纯化,洗脱剂:石油醚:乙酸乙酯=1:1~0:1,得到白色固体1.42g,即为化合物A。In a 100 ml single-necked flask, add trans-2- {1- [4- (N-tert-butoxycarbonyl) -amino] -cyclohexyl} acetaldehyde (1.5 g, 0.00622 mol), SM02 free base (1.36 g, 0.00622 mol, 1 eq), and dichloromethane (50 ml) was stirred and dissolved. Sodium triacetoxyborohydride (1.98 g, 0.00933 mol, 1.5 eq) was added in portions. After the addition was complete, the reaction was stirred overnight. Sampling to check the basic reaction is complete, the reaction solution was added 60ml saturated sodium bicarbonate and stirred for 30min, the liquid phase was separated, and the aqueous phase was extracted with dichloromethane (50ml * 2). , Spin-dried, purified by column chromatography, eluent: petroleum ether: ethyl acetate = 1: 1 to 0: 1, 1.42 g of white solid was obtained, which is compound A.
后续操作按照实施例4和5的方法制备化合物B和化合物IB。Subsequent operations: Compound B and compound IB were prepared according to the methods of Examples 4 and 5.
上述实验表明,本发明的方法制备的产物IB纯度高,大大降低了杂质含量、特别是二聚体杂质和单甲基杂质含量(单杂小于0.1%),容易达到药物质量标准。而且后处理简单,能够显著降低生产成本,因而更适合工业化大规模生产。The above experiments show that the product IB prepared by the method of the present invention has high purity, which greatly reduces the content of impurities, especially the content of dimer impurities and monomethyl impurities (mono impurity is less than 0.1%), and easily meets drug quality standards. Moreover, the post-processing is simple, which can significantly reduce the production cost, so it is more suitable for industrial large-scale production.

Claims (10)

  1. 一种制备式IB所示环己烷衍生物的方法,包括以下步骤:A method for preparing a cyclohexane derivative represented by Formula IB includes the following steps:
    (1)将化合物SM01与化合物SM02或其盐进行亲核取代反应,得化合物A;(1) Compound SM01 is subjected to a nucleophilic substitution reaction with compound SM02 or a salt thereof to obtain compound A;
    (2)化合物A脱保护,得到化合物B或化合物B的盐;(2) deprotection of compound A to obtain compound B or a salt of compound B;
    (3)化合物B或化合物B的盐,与含有N,N-二甲氨基甲酰基的酰化试剂进行酰化反应,即得化合物IB,(3) Compound B or a salt of compound B is subjected to an acylation reaction with an acylating agent containing N, N-dimethylcarbamoyl to obtain compound IB,
    合成路线为:The synthetic route is:
    Figure PCTCN2019100364-appb-100001
    Figure PCTCN2019100364-appb-100001
    其中R为:Where R is:
    Figure PCTCN2019100364-appb-100002
    Figure PCTCN2019100364-appb-100002
    R 2为氨基保护基;L为离去基团L’或-OH。 R 2 is an amino protecting group; L is a leaving group L 'or -OH.
  2. 根据权利要求1所述的方法,其特征在于,所述R 2为叔丁氧羰基Boc。 The method according to claim 1, wherein R 2 is tert-butoxycarbonyl Boc.
  3. 根据权利要求1所述的方法,其特征在于,所述L’为-OTs、-OMs、-Br、-Cl或-I。The method according to claim 1, wherein the L 'is -OTs, -OMs, -Br, -Cl, or -I.
  4. 根据权利要求1所述的方法,其特征在于,步骤(1)中当L为L’时,所述亲核取代反应在碱存在下进行,所述碱选自碳酸钾、碳酸钠、三乙胺或二异丙基乙基胺。The method according to claim 1, characterized in that when L is L 'in step (1), the nucleophilic substitution reaction is performed in the presence of a base selected from the group consisting of potassium carbonate, sodium carbonate, and triethyl Amine or diisopropylethylamine.
  5. 根据权利要求1所述的方法,其特征在于,步骤(1)中当L为-OH时,所述亲核取代反应是在钌催化剂Ru 3(CO) 12的催化下进行,膦配体选自Xantphos、Ruphos或Xphos。 The method according to claim 1, characterized in that when L is -OH in step (1), the nucleophilic substitution reaction is carried out under the catalysis of Ru 3 (CO) 12 ruthenium catalyst, and the phosphine ligand is selected From Xantphos, Ruphos or Xphos.
  6. 根据权利要求1所述的方法,其特征在于,步骤(1)中当L为L’时,化合物SM01由下述反应制得:The method according to claim 1, characterized in that when L is L 'in step (1), the compound SM01 is prepared by the following reaction:
    Figure PCTCN2019100364-appb-100003
    Figure PCTCN2019100364-appb-100003
  7. 根据权利要求6所述的方法,其特征在于,反应的试剂选自对甲苯磺酰氯、甲磺酰氯、NBS、二氯亚砜、三氯氧磷、碘或三溴化磷。The method according to claim 6, wherein the reagent for the reaction is selected from the group consisting of p-toluenesulfonyl chloride, methanesulfonyl chloride, NBS, dichlorosulfoxide, phosphorus oxychloride, iodine, or phosphorus tribromide.
  8. 根据权利要求1所述的方法,其特征在于,化合物SM02通过包含下述步骤的方法制得:The method according to claim 1, wherein the compound SM02 is prepared by a method comprising the following steps:
    ①R-X与R 1-哌嗪进行偶联反应,生成SM02-A; ① R-X is coupled with R 1 -piperazine to form SM02-A;
    ②SM02-A脱保护,得到化合物SM02或SM02的盐;②SM02-A is deprotected to obtain the compound SM02 or SM02 salt;
    合成路线为:The synthetic route is:
    Figure PCTCN2019100364-appb-100004
    Figure PCTCN2019100364-appb-100004
    其中,X为Cl、Br或I;R 1为氨基保护基。 Wherein, X is Cl, Br or I; R 1 is an amino protecting group.
  9. 根据权利要求1所述的方法,其特征在于,步骤(2)所述脱保护反应在酸存在下进行,所用的酸选自氯化氢、盐酸、硫酸或对甲苯磺酸。The method according to claim 1, wherein the deprotection reaction in step (2) is performed in the presence of an acid, and the acid used is selected from hydrogen chloride, hydrochloric acid, sulfuric acid, or p-toluenesulfonic acid.
  10. 根据权利要求1所述的方法,其特征在于,步骤(3)所述酰化反应的酰化试剂为N,N-二甲氨基甲酰氯,CDI和二甲胺,或者三光气和二甲胺。The method according to claim 1, characterized in that the acylating reagent in the acylation reaction in step (3) is N, N-dimethylcarbamoyl chloride, CDI and dimethylamine, or triphosgene and dimethylamine .
PCT/CN2019/100364 2018-08-14 2019-08-13 Method for preparing cyclohexane derivative WO2020034945A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810920768.9 2018-08-14
CN201810920768.9A CN110818680A (en) 2018-08-14 2018-08-14 Preparation method of cyclohexane derivative

Publications (1)

Publication Number Publication Date
WO2020034945A1 true WO2020034945A1 (en) 2020-02-20

Family

ID=69524703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/100364 WO2020034945A1 (en) 2018-08-14 2019-08-13 Method for preparing cyclohexane derivative

Country Status (2)

Country Link
CN (1) CN110818680A (en)
WO (1) WO2020034945A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202118758A (en) * 2019-11-05 2021-05-16 大陸商上海翰森生物醫藥科技有限公司 Benzothiophene derivative regulator, preparation method therefor and application thereof
CN114634479A (en) * 2020-12-16 2022-06-17 北京盈科瑞创新药物研究有限公司 Piperazine derivative, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130737A (en) * 2011-12-05 2013-06-05 江苏恒谊药业有限公司 Cyclohexane amine compound and application of cyclohexane amine compound as anti-schizophrenia medicine
WO2015056164A1 (en) * 2013-10-14 2015-04-23 Chemo Research, S.L. 1,4-cyclohexylamine derivatives and processes for the preparation thereof
WO2017045599A1 (en) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof
CN106543039A (en) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 It is a kind of for preparing compound of Cariliprazine and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518841B (en) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 Cyclohexane derivant or its stereoisomer or salt and its preparation and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130737A (en) * 2011-12-05 2013-06-05 江苏恒谊药业有限公司 Cyclohexane amine compound and application of cyclohexane amine compound as anti-schizophrenia medicine
WO2015056164A1 (en) * 2013-10-14 2015-04-23 Chemo Research, S.L. 1,4-cyclohexylamine derivatives and processes for the preparation thereof
WO2017045599A1 (en) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof
CN106543039A (en) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 It is a kind of for preparing compound of Cariliprazine and preparation method thereof

Also Published As

Publication number Publication date
CN110818680A (en) 2020-02-21

Similar Documents

Publication Publication Date Title
CN105283442B (en) Method for synthesizing 1 (2 ((2,4 3,5-dimethylphenyl) is thio) phenyl) piperazine
TWI454471B (en) Processes to make apoptosis promoters
RU2581585C2 (en) Method of producing 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl] amino} -carbonyl) amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, salts and monohydrate thereof
CN110381940B (en) AG-10 preparation method, intermediate and salt thereof
BRPI0914788B1 (en) process for producing an intermediate product of dabigatran etexylate
WO2015154637A1 (en) Method for preparing silodosin intermediate
WO2015165320A1 (en) Regorafenib salt and crystal form thereof, and preparation method
WO2020034945A1 (en) Method for preparing cyclohexane derivative
WO2023179068A1 (en) Drug intermediate and synthetic method, and isoquinoline derivative and synthetic method therefor
JP2023525951A (en) Compound based on glutarimide skeleton and use thereof
JP2019527228A (en) Novel compounds and methods
TWI530504B (en) Synthetic method of testosterone alkanoate
WO2020034946A1 (en) Method for preparing cyclohexane derivative
SK40696A3 (en) Process for the preparation of n-methyl-3-(1-methyl-4-piperidinyl)-1h-indole-5-etanesulfonamide and an intermediate product
CN110818678B (en) Method for preparing cyclohexane derivative
WO2022262548A1 (en) Preparation method for compound fasudil hydrochloride
CN110818677A (en) Process for the preparation of cyclohexane derivatives
TW202210486A (en) Method for preparing glp-1 receptor agonist
CN111269199B (en) Preparation method of cariprazine
EP3848361A1 (en) Method of producing tetracyclic compound
CN107778224A (en) A kind of preparation method of betrixaban intermediate
CN111100111B (en) Method for preparing benzothiophene derivative
CN111100110A (en) Process for preparing 7-piperazinylbenzothiophenes or salts thereof
WO2020125581A1 (en) Amide derivatives and preparation method for intermediates thereof
EP3906235B1 (en) Method for preparing sulfonamides drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19850053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19850053

Country of ref document: EP

Kind code of ref document: A1